Are there any side effects for prednisone in combination with abiraterone that are concerning for these patients?
The general side effect profile of abiraterone is fluid retention, hypertension, and potentially electrolyte abnormalities. And elderly patients, because of maybe a reduced cardiovascular reserve or other comorbidities, are simply more likely to have cardiovascular toxicities from anything that would cause fluid retention. So I would say that, for the elderly patient, we need to be particularly concerned about monitoring their cardiac status, their fluid status. Even, for example, having a patient weigh himself once a week or something like that at home is important because that’s probably the most sensitive indicator of whether fluid retention is occurring. And so when I see a patient, elderly or not, I will examine them for fluid retention, edema, pedal edema, and those types of things. If I notice a sudden or a drastic weight gain, or if I notice rales in the bases of their lungs, that would be something that would prompt me to think that they might need, for example, a diuretic or other approaches that could reduce the fluid retention.
The other issue is that it is safe and reasonable to reduce the dose of prednisone from 10 mg or 5 mg twice a day to 5 mg daily if a patient is experiencing prednisone-specific side effects. That obviously can be done, but monitoring needs to continue after that is done as well.
CASE: Metastatic Prostate Cancer (Part 1)
Stanley S is an 83-year-old Caucasian male whose past medical history includes diagnosis of adenocarcinoma of the prostate in 2012 with no evidence of metastasis. At the time, he was started on bicalutamide and his serum PSA levels subsequently decreased to 1.2 ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
January 2nd 2025The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Read More
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
December 31st 2024During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.
Read More